AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19280974 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (unprotected)
Number of subjects: 378
Study 19280974 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (unprotected)
Number of subjects: 378
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (protected)
Number of subjects: 378
Study 17883853 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient care program consisting of a workplace intervention based on participatory ergonomics and a graded activity program using cognitive behavioural principles.
Number of subjects: 0
Study 17883853 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by the medical specialist, occupational physician, general practitioner, and allied health professionals.
Number of subjects: 0
Study 17883853 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient care program
Number of subjects: 0
Study 17883853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 15355144 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual short-term memory task with visual interference
Number of subjects: 0
Study 15355144 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial memory task with spatial interference
Number of subjects: 0
Study 15355144 — intervention group
Group type: COMPARATOR
Intervention: Visual short-term memory task with spatial interference
Number of subjects: 0
Study 15355144 — intervention group
Group type: COMPARATOR
Intervention: Spatial memory task with visual interference
Number of subjects: 0
Study 11442522 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 100
Study 11442522 — intervention group
Group type: COMPARATOR
Intervention: Nylon darn
Number of subjects: 100
Study 9679573 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive radical surgery (Japanese operation)
Number of subjects: 0
Study 9679573 — intervention group
Group type: COMPARATOR
Intervention: TME (Total Mesorectal Excision)
Number of subjects: 0
Study 9679573 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-preserving operations (e.g., EMR)
Number of subjects: 0
Study 7585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 7585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical system
Number of subjects: 0
Study 1703598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intravenous isradipine
Number of subjects: 10
Study 1703598 — intervention group
Group type: COMPARATOR
Intervention: 2 mg intravenous nifedipine
Number of subjects: 10
Study 762032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 65
Study 762032 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 65
Study 762032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 29985679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (SP) supplementation
Number of subjects: 20
Study 29985679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28680540 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic Experiencing (SE) in addition to treatment-as-usual (TAU)
Number of subjects: 91
Study 28680540 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 91
Study 26444090 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066
Number of subjects: 560
Study 22247720 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + vitamin C (500 mg EPA and 200 mg vitamin C)
Number of subjects: 65
Study 22247720 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + placebo (500 mg EPA and placebo vitamin C)
Number of subjects: 65
Study 22247720 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + vitamin C (placebo EPA and 200 mg vitamin C)
Number of subjects: 65
Study 22247720 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo (placebo EPA and placebo vitamin C)
Number of subjects: 65
Study 19535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration (20 mL of ropivacaine 0.75%)
Number of subjects: 52
Study 19535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration
Number of subjects: 52
Study 19535716 — intervention group
Group type: COMPARATOR
Intervention: Control (IV acetaminophen combined with nalbuphine)
Number of subjects: 52
Study 17366241 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-based recovery model; 12 sessions in group format over two months
Number of subjects: 0
Study 15009362 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia with 1% lidocaine
Number of subjects: 90
Study 15009362 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic saline injection
Number of subjects: 90
Study 15009362 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 90
Study 11158416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-based immunosuppression (group 1)
Number of subjects: 38
Study 11158416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate-based immunosuppression (group 2)
Number of subjects: 38
Study 11158416 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (group 3)
Number of subjects: 38
Study 11158416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-based immunosuppression (group 1A)
Number of subjects: 38
Study 11158416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-based immunosuppression (group 1B)
Number of subjects: 38
Study 11158416 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at 28 weeks
Number of subjects: 38
Study 9517769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate (MTX) 0.3 mg/kg once weekly plus daily oral low dose prednisone
Number of subjects: 17
Study 9517769 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant prednisone dose of 7.5 mg/day
Number of subjects: 17
Study 9517769 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17
Study 9517769 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly low dose MTX in combination with low dose corticosteroids
Number of subjects: 17
Study 9869045 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomosis with one layer of suture (Gambee stitches)
Number of subjects: 86
Study 9869045 — intervention group
Group type: COMPARATOR
Intervention: Anastomosis with two layers of suture (first with Connel‐Mayo stitches then with Lembert)
Number of subjects: 86
Study 2785545 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate (Riopan)
Number of subjects: 30
Study 2785545 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide (Trigastril)
Number of subjects: 30
Study 142502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 12
Study 142502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 142502 — intervention group
Group type: COMPARATOR
Intervention: Control (no aerosol)
Number of subjects: 12
Study 30831579 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Up Milk 'Lite' (GUMLi)
Number of subjects: 160
Study 30831579 — intervention group
Group type: COMPARATOR
Intervention: Standard cow milk
Number of subjects: 160
Study 30831579 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GUMLi and cow milk
Number of subjects: 160
Study 30831579 — intervention group
Group type: EXPERIMENTAL
Intervention: GUMLi
Number of subjects: 160
Study 27513822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-liberal strategy
Number of subjects: 1000
Study 27513822 — intervention group
Group type: COMPARATOR
Intervention: Fluid-conservative strategy
Number of subjects: 1000
Study 26070589 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in cereal fiber, free of red meat, and high in coffee (n = 13)
Number of subjects: 28
Study 26070589 — intervention group
Group type: COMPARATOR
Intervention: Diet low in fiber, high in red meat, and coffee free (n = 15)
Number of subjects: 28
Study 23672928 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25mg i.v. administered weekly in 4 week cycles
Number of subjects: 38
Study 21692021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radio-frequency ablation
Number of subjects: 187
Study 21692021 — intervention group
Group type: COMPARATOR
Intervention: Microwave ablation
Number of subjects: 187
Study 19573479 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 409
Study 19573479 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 409
Study 16406909 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative behavioral training
Number of subjects: 125
Study 16406909 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 125
Study 14729291 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured presentation (illustrated chart explaining the process and possible outcomes of screening, followed by screeners checking understanding)
Number of subjects: 40
Study 14729291 — intervention group
Group type: COMPARATOR
Intervention: Standard presentation (leaflet and short verbal explanation of the test)
Number of subjects: 40
Study 12526313 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF and alpha-INF joint treatment (experimental group)
Number of subjects: 36
Study 12526313 — intervention group
Group type: COMPARATOR
Intervention: alpha-INF alone (control group)
Number of subjects: 36
Study 9395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg
Number of subjects: 56
Study 9395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate 1 mg
Number of subjects: 56
Study 9395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol implants 50 mg
Number of subjects: 56
Study 9395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol + medroxyprogesterone acetate (MPA) 2 mg + 5 mg
Number of subjects: 56
Study 9395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol + norethisterone acetate (NE) 2 mg + 1 mg
Number of subjects: 56
Study 8195446 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pressure‐controlled probing set at 25 g
Number of subjects: 100
Study 8195446 — intervention group
Group type: COMPARATOR
Intervention: Hand probing (conventional method)
Number of subjects: 100
Study 3273871 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal 1 + 1
Number of subjects: 36
Study 3273871 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuart Prenatal
Number of subjects: 36
Study 3273871 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 36
Study 3273871 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalins Rx
Number of subjects: 36
Study 31416637 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataGraft tissue
Number of subjects: 30
Study 31416637 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 30
Study 28030444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0 mg/kg)
Number of subjects: 125
Study 28030444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.05 mg/kg)
Number of subjects: 125
Study 28030444 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous recovery
Number of subjects: 125
Study 28030444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 26607841 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 51
Study 26607841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23877110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided periradicular injections
Number of subjects: 40
Study 23877110 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography-controlled periradicular injections
Number of subjects: 40
Study 21920865 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash-associated disorders (WAD) patients
Number of subjects: 91
Study 21920865 — intervention group
Group type: COMPARATOR
Intervention: Noninjured neck pain controls
Number of subjects: 91
Study 19491335 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0657 7 mg
Number of subjects: 16
Study 19491335 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa 25/250 mg (LD)
Number of subjects: 16
Study 19491335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16490488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral LASIK with superior-hinge Hansatome microkeratome (n = 17)
Number of subjects: 35
Study 16490488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral LASIK with nasal-hinge Amadeus microkeratome (n = 18)
Number of subjects: 35
Study 16490488 — intervention group
Group type: COMPARATOR
Intervention: Preoperative myopia
Number of subjects: 35
Study 16490488 — intervention group
Group type: COMPARATOR
Intervention: Laser-calculated ablation depth
Number of subjects: 35
Study 16490488 — intervention group
Group type: COMPARATOR
Intervention: Combined ablation depth and flap thickness
Number of subjects: 35
Study 15573453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Number of subjects: 2934
Study 15573453 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2934
Study 15573453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2934
Study 10758447 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg kg-1 plus dexamethasone 8 mg
Number of subjects: 120
Study 10758447 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 40 microg kg-1
Number of subjects: 120
Study 9438777 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 angiotensin II receptor antagonist)
Number of subjects: 0
Study 9438777 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 0
Study 9438777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8395719 — intervention group
Group type: EXPERIMENTAL
Intervention: LU 47311 (reviparin)
Number of subjects: 41
Study 3468891 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tar cigarettes (5 mg/cig.)
Number of subjects: 0
Study 3468891 — intervention group
Group type: COMPARATOR
Intervention: Medium-tar cigarettes (15 mg/cig.)
Number of subjects: 0
Study 31237947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg/d for 24 weeks
Number of subjects: 77
Study 31237947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 31237947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 77
Study 29391360 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2700 mg)
Number of subjects: 300
Study 29391360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 26897383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose glucagon stimulation test (FD-GST: 1 or 1.5 mg in patients >90 kg)
Number of subjects: 28
Study 26897383 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based glucagon stimulation test (WB-GST: 0.03 mg/kg)
Number of subjects: 28
Study 26897383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose glucagon stimulation test (FD-GST)
Number of subjects: 28
Study 26897383 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based glucagon stimulation test (WB-GST)
Number of subjects: 28
Study 24296325 — intervention group
Group type: EXPERIMENTAL
Intervention: HMM+SMC
Number of subjects: 0
Study 24296325 — intervention group
Group type: COMPARATOR
Intervention: HMM
Number of subjects: 0
Study 22790107 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive in-home comprehensive geriatric assessment (CGA) performed by trained medical students using the STEP-tool
Number of subjects: 1620
Study 22790107 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care (Control)
Number of subjects: 1620
Study 20003095 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverine citrate 60 mg with simeticone 300 mg three times daily for 4 weeks
Number of subjects: 412
Study 20003095 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 4 weeks
Number of subjects: 412
Study 17706655 — intervention group
Group type: EXPERIMENTAL
Intervention: Small hand paddles (116 cm²)
Number of subjects: 8
Study 17706655 — intervention group
Group type: EXPERIMENTAL
Intervention: Large hand paddles (268 cm²)
Number of subjects: 8
Study 17706655 — intervention group
Group type: COMPARATOR
Intervention: No paddles (control)
Number of subjects: 8
Study 16228857 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-tip laparoscopes (Olympus LTF-V3 and Fujinon EL2-TF310)
Number of subjects: 29
Study 16228857 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees lens rigid laparoscope
Number of subjects: 29
Study 16228857 — intervention group
Group type: COMPARATOR
Intervention: 0 degrees lens rigid laparoscope
Number of subjects: 29
Study 12744893 — intervention group
Group type: EXPERIMENTAL
Intervention: Men C-CRM(197) conjugate vaccine
Number of subjects: 193
Study 10232438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy and bronchoalveolar lavage (BAL) in skiers
Number of subjects: 40
Study 10232438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) fluid analysis in skiers
Number of subjects: 40
Study 10232438 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of inflammatory markers in skiers
Number of subjects: 40
Study 10232438 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of inflammatory index in skiers with ski asthma
Number of subjects: 40
Study 10232438 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte subtypes and activation markers in skiers
Number of subjects: 40
Study 10232438 — intervention group
Group type: COMPARATOR
Intervention: Concentration of albumin, fibronectin, and hyaluronan in skiers
Number of subjects: 40
Study 8734400 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion of vision via opaque goggles
Number of subjects: 2
Study 8734400 — intervention group
Group type: COMPARATOR
Intervention: No visual occlusion
Number of subjects: 2
Study 6362017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for 7 days
Number of subjects: 77
Study 6362017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for the first 4 days then 15 mg base per kg body wt. 8 hourly for the next 3 days
Number of subjects: 77
Study 6362017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per kg body wt. 8 hourly for 7 days and then sulfadoxine 30 mg per kg body wt. and pyrimethamine 1.5 mg per kg body wt.
Number of subjects: 77
Study 29958706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged white wine (AWW)
Number of subjects: 38
Study 29958706 — intervention group
Group type: COMPARATOR
Intervention: Gin
Number of subjects: 38
Study 28362563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadila MMR vaccine
Number of subjects: 328
Study 28362563 — intervention group
Group type: COMPARATOR
Intervention: Serum MMR vaccine
Number of subjects: 328
Study 27798034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic tranexamic acid
Number of subjects: 100
Study 27798034 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic platelet transfusions
Number of subjects: 100
Study 23815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational speech (Experiment 1)
Number of subjects: 0
Study 23815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear speech (Experiment 2)
Number of subjects: 0
Study 23815478 — intervention group
Group type: COMPARATOR
Intervention: Noise (Experiment 3a)
Number of subjects: 0
Study 23815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load (Experiments 4a and 4b)
Number of subjects: 0
Study 22081489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5‐3.5 mg/day) with or without prednisone
Number of subjects: 94
Study 19176240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children throughout PICU stay (n=349)
Number of subjects: 700
Study 19176240 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy to prevent blood glucose from exceeding 11.9 mmol/L (n=351)
Number of subjects: 700
Study 17209701 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced negative mood
Number of subjects: 311
Study 17209701 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced mood (general)
Number of subjects: 311
Study 15934104 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain group (hip or knee pain at both baseline and follow-up)
Number of subjects: 3210
Study 15934104 — intervention group
Group type: COMPARATOR
Intervention: Non-persistent pain group (hip or knee pain at baseline but no pain at follow-up)
Number of subjects: 3210
Study 12741451 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee brewed with conduction roasting
Number of subjects: 30
Study 12741451 — intervention group
Group type: COMPARATOR
Intervention: Control coffee (differently processed coffee)
Number of subjects: 30
Study 8734235 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone 1.5 mg.kg‐1 intravenously at the beginning of surgery and 1.5 mg.kg‐1 iv daily for three days after surgery)
Number of subjects: 32
Study 8734235 — intervention group
Group type: COMPARATOR
Intervention: PANHD (preoperative acute normovolaemic haemodilution)
Number of subjects: 32
Study 1827006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg isradipine twice daily
Number of subjects: 45
Study 1827006 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg isradipine twice daily
Number of subjects: 45
Study 1827006 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isradipine twice daily
Number of subjects: 45
Study 7053912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4
Study 7053912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol combined with lactate and glycerol infusions
Number of subjects: 4
Study 7053912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 29946756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU of cholecalciferol weekly for 24 weeks)
Number of subjects: 180